SGLT2 inhibitors serve as a foundational therapy for cardiovascular outcomes in patients with heart failure with preserved and mildly reduced ejection fraction regardless of diabetes.
Meta-Analysis
Heart failure with mildly reduced and preserved ejection fraction
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs Placebo
Cardiovascular death and/or urgent visits/hospitalization for heart failure
AIM: To provide a pooled effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF: ≥50%) or/and mildly reduced EF (HFmrEF: 41-49%) regardless of baseline diabetes. METHODS: We systemically searched PubMed/MEDLINE, Embase, Web of Science databases and clinical trial registries using appropriate keywords till August 28, 2022, to identify randomized controlled trials (RCTs) or post-hoc analysis of RCTs, reporting cardiovascular death (CVD) and/or urgent visits/hospitalization for heart failure(HHF) in patients with HFmrEF/HFpEF receiving SGLTi vs. placebo. Hazard ratios (HR) with 95% confidence intervals (CI) for outcomes were pooled together using generic inverse variance method with fixed-effects model. RESULTS: = 0%). CONCLUSIONS: This meta-analysis established the place of SGLT2i as a foundational therapy among patients with HF with preserved and mildly reduced EF regardless of diabetes.
Building similarity graph...
Analyzing shared references across papers
Loading...
Mainak Banerjee
Ramakrishna Mission Vidyamandira
Rimesh Pal
Post Graduate Institute of Medical Education and Research
Kirthana Nair
Post Graduate Institute of Medical Education and Research
Indian Heart Journal
Post Graduate Institute of Medical Education and Research
Institute of Post Graduate Medical Education and Research
Building similarity graph...
Analyzing shared references across papers
Loading...
Banerjee et al. (Wed,) conducted a meta-analysis in Heart failure with mildly reduced and preserved ejection fraction. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. Placebo was evaluated on Cardiovascular death and/or urgent visits/hospitalization for heart failure. SGLT2 inhibitors serve as a foundational therapy for cardiovascular outcomes in patients with heart failure with preserved and mildly reduced ejection fraction regardless of diabetes.
synapsesocial.com/papers/6a07b4e315d371b3883868c4 — DOI: https://doi.org/10.1016/j.ihj.2023.03.003
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: